International Stem Cell Corporation (ISCO) passes another Milestone in its Quest for a Parkinson’s Cure
On March 7, 2016, International Stem Cell Corporation (OTCQB: ISCO) announced that the Melbourne Health Human Research Ethics Committee (HREC) had approved its application to initiate phase I clinical trials of ISC-hpNSC® (human parthenogenetic neural stem cells) for the treatment of moderate to severe Parkinson's disease. With that approval, ISCO has begun enrolling patients for those phase I clinical trials in what marks a major milestone for the company. International Stem Cell Corporation is researching new ways to increase the quality and length of human life spans through regenerative technologies that augment or replace organ transplants, developments made possible by…